Consists of Caffeine, Chlorpheniramine, Paracetamol, Phenylephrine
Pregnancy of Caffeine (Xykaa PLUS) in details
Caffeine (Xykaa PLUS) crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Grosso 2005).
Based on current studies, usual dietary exposure to Caffeine (Xykaa PLUS) is unlikely to cause congenital malformations (Brent 2011). However, available data show conflicting results related to maternal Caffeine (Xykaa PLUS) use and the risk of other adverse events, such as spontaneous abortion or growth retardation (Brent 2011; Jahanfar 2013; Nehlig 1994). Chronic maternal consumption of high amounts of Caffeine (Xykaa PLUS) during pregnancy may lead to neonatal withdrawal at delivery (eg, apnea, irritability, jitteriness, vomiting) (Martin 2007).
The half-life of Caffeine (Xykaa PLUS) is prolonged during the second and third trimesters of pregnancy and maternal and fetal exposure is also influenced by maternal tobacco or alcohol consumption (Brent 2011; Koren 2000). Current guidelines recommend limiting Caffeine (Xykaa PLUS) intake from all sources to ≤200 mg/day during pregnancy (ACOG 2010).
Caffeine (Xykaa PLUS) breastfeeding
Caffeine (Xykaa PLUS) citrate is not indicated for use in adult patients. Excreted into human milk: Yes Comments: -Caffeine (Xykaa PLUS) readily crosses the placenta into the fetal circulation. -Breastfeeding mothers of infants receiving Caffeine (Xykaa PLUS) citrate should not ingest Caffeine (Xykaa PLUS)-containing foods, beverages, and medicinal products.
See references
References for pregnancy information
- "Product Information. Cafcit (Caffeine (Xykaa PLUS))" Roxane Laboratories Inc, Columbus, OH.
References for breastfeeding information
- "Product Information. Cafcit (Caffeine (Xykaa PLUS))" Roxane Laboratories Inc, Columbus, OH.
Pregnancy of Chlorpheniramine (Xykaa PLUS) in details
The Collaborative Perinatal Project monitored 1,070 first trimester exposures and 3,931 exposures which occurred anytime during pregnancy. No evidence was found to suggest a relationship to large categories of malformations. Antihistamine exposure in the first trimester in general was not associated with an increased risk of malformations.
Chlorpheniramine has been assigned to pregnancy category B by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. Chlorpheniramine is only recommended for use during pregnancy when benefit outweighs risk.
See references
Chlorpheniramine (Xykaa PLUS) breastfeeding
There are no data on the excretion of chlorpheniramine into human milk. However, because other antihistamines are excreted into human milk in low concentrations, the manufacturer recommends that caution be used when administering chlorpheniramine to nursing women.
See references
References for pregnancy information
- "Product Information. Chlortrimeton (chlorpheniramine)." Schering-Plough, Liberty Corner, NJ.
- Black RA, Hill DA "Over-the-counter medications in pregnancy." Am Fam Physician 67 (2003): 2517-24
- Heinonen O, Slone D, Shapiro S; Kaufman DW ed. "Birth Defects and Drugs in Pregnancy." Littleton, MA: Publishing Sciences Group, Inc. (1977): 297
- Nelson MA, Forfar JO "Associations between drugs administered during pregnancy and congenital abnormalities of the fetus." Br Med J 1 (1971): 523-7
References for breastfeeding information
- "Product Information. Chlortrimeton (chlorpheniramine)." Schering-Plough, Liberty Corner, NJ.
Pregnancy of Paracetamol (Xykaa PLUS) in details
During pregnancy patients should avoid prolonged use of Paracetamol (Xykaa PLUS) Zodley Pharmaceuticals because the risk of addiction in the fetus and the occurrence of withdrawal in the neonatal period.
If necessary using in lactation (breastfeeding) should be aware that tramadol in small amounts excreted in breast milk. In the case of long-term treatment can not been excluded the possibility of drug dependence.
Paracetamol (Xykaa PLUS) Zodley Pharmaceuticals is not recommended for treatment of withdrawal syndrome drugs.
Patients need to avoid combination with MAO inhibitors.
During the period of treatment with Paracetamol (Xykaa PLUS) Zodley Pharmaceuticals you should avoid to take alcohol.
Tramadol in the form of long-acting formulations should not be used in children under the age of 14 years.
During the period of tramadol using is not recommended to engage in activities that require special attention, speed of psychomotor reactions.
Pregnancy of Phenylephrine (Xykaa PLUS) in details
Phenylephrine (Xykaa PLUS) crosses the placenta at term.
Maternal use of Phenylephrine (Xykaa PLUS) during the first trimester of pregnancy is not strongly associated with an increased risk of fetal malformations; maternal dose and duration of therapy were not reported in available publications. Phenylephrine (Xykaa PLUS) is available over-the-counter for the symptomatic relief of nasal congestion. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy.
Oral Phenylephrine (Xykaa PLUS) should be avoided during the first trimester of pregnancy; short-term use (<3 days) of intranasal Phenylephrine (Xykaa PLUS) may be beneficial to some patients although its safety during pregnancy has not been studied. Phenylephrine (Xykaa PLUS) injection is used at delivery for the prevention and/or treatment of maternal hypotension associated with spinal anesthesia in women undergoing cesarean section. Phenylephrine (Xykaa PLUS) may be associated with a more favorable fetal acid base status than ephedrine; however, overall fetal outcomes appear to be similar. Nausea or vomiting may be less with Phenylephrine (Xykaa PLUS) than ephedrine but is also dependent upon blood pressure control. Phenylephrine (Xykaa PLUS) may be preferred in the absence of maternal bradycardia.
Phenylephrine (Xykaa PLUS) breastfeeding
Small amounts of Phenylephrine (Xykaa PLUS) are secreted in breast milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
See references
References for pregnancy information
- "Product Information. Lusonal (Phenylephrine (Xykaa PLUS))." Wraser Pharmaceuticals, Ridgeland, MS.
References for breastfeeding information
- "Product Information. Lusonal (Phenylephrine (Xykaa PLUS))." Wraser Pharmaceuticals, Ridgeland, MS.
References
- DailyMed. "CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CAFFEINE; ERGOTAMINE TARTRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubMed Health. "Chlorpheniramine (By mouth): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
